Similar Search Results

The contribution of pharmaceutical innovation to longevity growth in Germany and France

Lichtenberg, Frank R. - 2010

-adjusted mortality rates of residents of Germany, using longitudinal, annual, state-level data during the period 2000-2007. The estimates …-adjusted cancer mortality rates of residents of France, using longitudinal, annual, cancer-site-level data during the period 2002 … mortality rates, and may have accounted for as much as half of the decline. …

Persistent link: https://www.econbiz.de/10003977959

How did U.S. consumers use their stimulus payments?

Coibion, Olivier; Gorodnichenko, Yuriy; Weber, Michael - 2020

Using a large-scale survey of U.S. consumers, we study how the large one-time transfers to individuals from the CARES Act affected their consumption, saving and labor-supply decisions. Most respondents report that they primarily saved or paid down debts with their transfers, with only about 15...

Persistent link: https://www.econbiz.de/10012263377

The cost of the COVID-19 crisis : lockdowns,macroeconomic expectations, and consumer spending

Coibion, Olivier; Gorodnichenko, Yuriy; Weber, Michael - 2020

We study how the differential timing of local lockdowns due to COVID-19 causally affects households’ spending and macroeconomic expectations at the local level using several waves of a customized survey with more than 10,000 respondents. About 50% of survey participants report income and...

Persistent link: https://www.econbiz.de/10012219342

Response to Baker and Fugh-Berman's critique of my paper, "Why has longevity increased more in some states than in others?"

Lichtenberg, Frank R. - 2009

study was subject to a number of major methodological flaws. Many of their claims pertain to the role of infant mortality …. I show that infant mortality was not an important determinant of the growth in U.S. life expectancy during the period … that I studied, and that my estimates are completely insensitive to the inclusion or exclusion of infant mortality …

Persistent link: https://www.econbiz.de/10003861794

The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010 : evidence from longitudinal, disease-level data

Lichtenberg, Frank R.; Pettersson, Billie - 2012

We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by...

Persistent link: https://www.econbiz.de/10009571756

Sources of US longevity increase, 1960 - 1997

Lichtenberg, Frank R. - 2000

Between 1960 and 1997, life expectancy at birth of Americans increased approximately 10% G from 69.7 to 76.5 years G and it has been estimated that the value of life extension during this period nearly equaled the gains in tangible consumption. While life expectancy has tended to increase, there...

Persistent link: https://www.econbiz.de/10011397757

The impact of recent chemotherapy innovation on the longevity of Myeloma patients : U.S. and international evidence

Lichtenberg, Frank R.; Hostenkamp, Gisela - 2013

myeloma mortality rate using longitudinal country-level data on 26 countries during the period 2005-2009. Countries that had … larger increases in the number of chemotherapy regimens had larger subsequent declines in myeloma mortality rates …, controlling for other factors. The estimates imply that chemotherapy innovation reduced the age-adjusted myeloma cancer mortality …

Persistent link: https://www.econbiz.de/10010223067

The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries : a two-way fixed-effects analysis

Lichtenberg, Frank R. - 2019

There are two types of prescription drug cost offsets. The first type of cost offset - from prescription drug use - is primarily about the effect of changes in drug quantity (e.g. due to changes in out-of-pocket drug costs) on other medical costs. The second type of cost offset - the cost offset...

Persistent link: https://www.econbiz.de/10011987056

How cost effective are new cancer drugs in the U.S.?

Lichtenberg, Frank R. - 2017

mortality from the cancers that had larger increases in the number of drugs ever approved, controlling for the change in cancer …

Persistent link: https://www.econbiz.de/10011735934

Spurious correlation in estimation of the health production function: A note

Akkoyunlu, Sule; Lichtenberg, Frank R.; Siliverstovs, Boriss - 2009

In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious correlation entails the risk of linking health status to medical (and nonmedical) inputs when no links exist. This note first presents the bounds testing procedure as a method to...

Persistent link: https://www.econbiz.de/10010315553